Clear Search

Showing 5 results for “patient-reported outcomes”.

July 2023

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

J Rheumatol. 2023 Jun 15:jrheum.2023-0060 DOI: 10.3899/jrheum.2023-0060

An analysis of the California Lupus Epidemiology Study cohort demonstrated that more than a quarter of participants reported at least one medication cost concern, which was associated with worse patient-reported outcomes. These results reveal a potentially modifiable risk factor for poor outcomes rooted in the unaffordability of lupus care.

more…

June 2023

Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial

Arthritis Rheumatol. 2023 doi: 10.1002/art.42557. Epub ahead of print.

This phase II study of BI 655064 in patients with active LN did not meet the primary endpoint of CRR at Week 52, however, post-hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.

more…

October 2022

Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature

Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188

Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.

more…

March 2022
February 2022

Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus

Clin Exp Rheumatol. 2021.Epub ahead of print

Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).

Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.

more…